Creabilis hires chief medical officer
Dr David Roblin joins the firm after holding leading roles at Pfizer and Bayer
Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years. He has held leadership roles at Pfizer and Bayer across a range of therapy areas in research, development and commercial roles.
At Pfizer, Roblin was most recently senior vice president, head of research and site head for European r&d. Before this, he was head of anti-infectives at Bayer Medical Affairs.
In addition Roblin has chaired the research director’s group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a US$2bn public-private partnership with the European Commission.
You may also like
Ingredients
![UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny]()
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny
The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Pharmaceutical
![OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics]()
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics
The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows
Pharmaceutical
![Pharma’s silent sustainability risk and the supply chain fix]()
Pharma’s silent sustainability risk and the supply chain fix
Pharma is making efforts to cut emissions from its own operations: shifting to renewables, upgrading facilities, streamlining logistics²⁰. But a significant share of emissions still hides outside the company’s direct control – yet in plain sight. Now, regulators and investors are turning their focus beyond the factory gates, deep into the value chain. What they’re finding is already reshaping the rules of competitiveness, capital access, and compliance. One of pharma’s most overlooked risks is quietly moving into the foreground. And the time to act is narrowing
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
